Retinal Degenerations Recruiting Phase 3 Trials for Aflibercept (DB08885)

Also known as: Retinal Degeneration / Degeneration retinal

IndicationStatusPhase
DBCOND0041282 (Retinal Degenerations)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04005352Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)Treatment